0
Avandia Hearing Reveals Fundamental Flaws at FDA
Union of Concerned Scientists
The advisory panel met yesterday and today to review safety questions regarding Avandia, a GlaxoSmithKline diabetes drug that has been linked to heart
Avandia: The Key Vote Is NegativeForbes (blog)
Close the FDA Approval GapHuffington Post (blog)
Whistleblower News Roundup 7.15.10Government Accountability Project (blog)

all 5 news articles »

Continue Reading

0
Panel Doesn't Recommend Pulling Avandia
OzarksFirst.com (blog)
The FDA was hoping to end the debate over whether Avandia was too dangerous to sell to diabetics. The drug has been under fire since 2007 when the first
The Avandia ControversyWebMD (blog)
Avandia's Sales Drop Far Behind ActosNew York Times (blog)
Avandia decision could bolster rivals' salesMedical Marketing and Media

all 3 news articles »

Continue Reading

0

Washington Post

Continue Reading

0

TheBull.com.au
European shares tumble, economy concerns persist
Reuters
L) added 1.8 percent in a relief rally after a US panel of health experts voted to keep the drugmaker's diabetes pill Avandia on the market but with new
European stocks resume rally after JPMorgan resultsReuters
European stocks dip; eyes on JPMorgan resultsReuters
Closing stock market indices outside the USForexyard

all 37 news articles »

Continue Reading

0

The Guardian
Glaxo's Shares Rise on Improved Outlook
New York Times (blog)
The British company took a public beating Wednesday in a split vote by a Food and Drug Administration advisory committee over the diabetes drug Avandia.
Glaxo To Book GBP1.57B To Settle Litigation, Including AvandiaWall Street Journal
Glaxo takes $2.4 bln charge, Avandia mostly settledReuters
Glaxo To Take $2.4 Billion Charge To Cover Avandia Cases, Other Legal WoesNPR (blog)
MarketWatch -Stop Press News (blog) -BNET
all 146 news articles »

Continue Reading